ReviewActa veterinaria Scandinavica2020
Towards improvements in foot-and-mouth disease vaccine performance.
Review in Acta veterinaria Scandinavica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and meta-analysis of the effectiveness of polypeptide, virus-like particles, and viral vector vaccines for foot-and-mouth disease (2020-2025).Scientific reports · 2025Pooled it
- Review
- Serotype Characterization and Transmission Modelling of Foot-and-Mouth Disease in Dairy Farms, Bishoftu, Ethiopia.Veterinary medicine and science · 2026Article
- Immunoinformatics-based design of artificial chimeric proteins as universal vaccine candidates against foot-and-mouth disease virus serotypes A, O, and SAT2.Scientific reports · 2026Article
- M13 phage-based antigen presentation and immune response activation in vaccine development for animal infectious diseases.Frontiers in immunology · 2026Review
- Robust cross-immunity against a heterologous field strain of foot-and-mouth disease virus achieved in small ruminants following commercial vaccination in Jordan.Frontiers in veterinary science · 2026Article
- Phylogenetic and evolutionary analysis of VP1 coding sequences of foot-and-mouth disease virus serotypes A, O, and SAT2 in Egypt.Virology journal · 2025Article
- Development and immunogenicity of adenoviral Fc-fused FMDV virus-like particle vaccine in swine.The veterinary quarterly · 2025Article
- Evaluation of applied foot and mouth disease-providing measures in the Republic of Armenia: A retrospective study.Open veterinary journal · 2025Article
- Monoclonal antibodies in veterinary antiviral immunotherapy: technologies, applications and challenges.Veterinary research communications · 2025Review
- Foot-and-Mouth Disease Virus-like Particles Produced inVeterinary sciences · 2025Article
- An antigen panel to assess the regional relevance of foot and mouth disease vaccines.NPJ vaccines · 2025Article
- Determination of risk factors for foot and mouth disease emergence in East Java, Indonesia.Open veterinary journal · 2025Article
- Current trends and challenges in the management of foot and mouth disease in Saudi Arabia: A review.Open veterinary journal · 2025Review
- Design and application of expression constructs for FMDV serotype O structural proteins.Biotechnology letters · 2025Article
- Foot-and-mouth disease: genomic and proteomic structure, antigenic sites, serotype relationships, immune evasion, recent vaccine development strategies, and future perspectives.Veterinary research · 2025Review
- Systematic follow-up investigation of NSP seroreactors and in-contact cattle and buffaloes for foot-and-mouth disease virus using probang sampling.BMC veterinary research · 2025Article
- Spatial-temporal distribution and risk factors of foot and mouth disease outbreaks in Java Island, Indonesia from 2022 to 2023.BMC veterinary research · 2025Article
- A novel immunoinformatic approach for design and evaluation of heptavalent multiepitope foot-and-mouth disease virus vaccine.BMC veterinary research · 2025Article
- Oral Administration of Zinc Sulfate with Intramuscular Foot-and-Mouth Disease Vaccine Enhances Mucosal and Systemic Immunity.Vaccines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foot-and-mouth disease (FMD) remains one of the most economically important infectious diseases of production animals. Six (out of 7 that have been identified) different serotypes of the FMD virus continue to circulate in different parts of the world. Within each serotype there is also extensive diversity as the virus constantly changes. Vaccines need to be "matched" to the outbreak strain, not just to the serotype, to confer protection. Vaccination has been used successfully to assist in the eradication of the disease from Europe but is no longer employed there unless outbreaks occur. Thus the animal population in Europe, as in North America, is fully susceptible to the virus if it is accidentally (or deliberately) introduced. Almost 3 billion doses of the vaccine are made each year to control the disease elsewhere. Current vaccines are produced from chemically inactivated virus that has to be grown, on a large scale, under high containment conditions. The vaccine efficiently prevents disease but the duration of immunity is rather limited (about 6 months) and vaccination does not provide sterile immunity or block the development of carriers. Furthermore, the vaccine is quite unstable and a cold chain needs to be maintained to preserve the efficacy of the vaccine. This can be a challenge in the parts of the world where the disease is endemic. There is a significant interest in developing improved vaccines and significant progress in this direction has been made using a variety of approaches. However, no alternative vaccines are yet available commercially. Improved disease control globally is clearly beneficial to all countries as it reduces the risk of virus incursions into disease free areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.